Reduction in death seen at 28, 60 days for patients receiving invasive mechanical ventilation, extracorporeal membrane oxygenation
Your search for baricitinib returned 17 results
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
But placebo-controlled trial shows lower all-cause mortality at 28 days and 60 days in patients receiving baricitinib plus standard of care
The update was based on data from the COV-BARRIER study.
Long-term sustained outcomes seen among adults with moderate-to-severe atopic dermatitis
Results from 2 studies show statistically significant improvement in scalp hair regrowth with baricitinib, a JAK inhibitor.
Findings showed that the trial did not meet statistical significance on the primary endpoint.
Methods to prevent and treat COVID-19 in cancer patients have had to evolve alongside the SARS-CoV-2 virus.
Compared with dual therapy, significant survival benefit seen with dexamethasone, remdesivir, and baricitinib but no change in length of stay
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of June. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…